Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Lymphoid 14Other hematologic neoplasm 12Plasma cell 8Thoracic 6Gastrointestinal 3Gynecologic 2Tumor-Agnostic 1Myeloid 1Head & Neck 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Paclitaxel 575Carboplatin 520Cisplatin 347Bevacizumab 252pembrolizumab 226Gemcitabine 157Topotecan 128liposomal doxorubicin 127Cyclophosphamide 126olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 80niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 56Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Maintenance × Gynecologic × Clear all
NCT06714084 2024-12-03

CNCMT

Hubei Cancer Hospital

Phase NA Enrolling by invitation
20 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT03983226 2022-03-18

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

Shanghai Gynecologic Oncology Group

Phase 2 Recruiting
167 enrolled
Gynecologic

Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡